The global cell and gene therapy market is expected to grow from USD 8.94 billion in 2025 to USD 39.61 billion by 2034, at a CAGR of 17.98%. North America leads the market, driven by high clinical trial activity and corporate R&D. Cell therapy for infectious diseases is the dominant segment, with innovations like gene editing tools and strategic partnerships fueling growth. However, high costs, regulatory challenges, and safety concerns remain key hurdles.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Gene Therapy Market, by Therapy Type
8.1.1. Cell Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Gene Therapy
8.1.2.1. Market Revenue and Forecast
9.1. Cell and Gene Therapy Market, by Indication / Therapeutic Area
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast
9.1.2. Genetic Disorders
9.1.2.1. Market Revenue and Forecast
9.1.3. Neurological Disorders
9.1.3.1. Market Revenue and Forecast
9.1.4. Cardiovascular Diseases
9.1.4.1. Market Revenue and Forecast
9.1.5. Ophthalmology
9.1.5.1. Market Revenue and Forecast
10.1. Cell and Gene Therapy Market, by Vector Type (Gene Delivery Method)
10.1.1. Viral Vectors
10.1.1.1. Market Revenue and Forecast
10.1.2. Non-Viral Vectors
10.1.2.1. Market Revenue and Forecast
11.1. Cell and Gene Therapy Market, by Manufacturing Type
11.1.1. In-house (Biotech/Pharma-Owned Facilities)
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Development & Manufacturing Organizations (CDMOs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Hybrid Models (e.g., early stage in-house, scale-up outsourced)
11.1.3.1. Market Revenue and Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Forecast
12.1. Cell and Gene Therapy Market, by End User
12.1.1. Hospitals and Specialty Clinics (administering therapies)
12.1.1.1. Market Revenue and Forecast
12.1.2. Academic and Research Institutes (preclinical development)
12.1.2.1. Market Revenue and Forecast
12.1.3. Biopharma and Biotech Companies
12.1.3.1. Market Revenue and Forecast
12.1.4. CDMOs and CROS
12.1.4.1. Market Revenue and Forecast
12.1.5. Government/Public Health Bodies (NIH, EMA programs)
12.1.5.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy Type
13.1.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.1.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.1.4. Market Revenue and Forecast, by Manufacturing Type
13.1.5. Market Revenue and Forecast, by End User
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy Type
13.1.6.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.1.6.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.1.6.4. Market Revenue and Forecast, by Manufacturing Type
13.1.6.5. Market Revenue and Forecast, by End User
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Therapy Type
13.1.7.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.1.7.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.1.7.4. Market Revenue and Forecast, by Manufacturing Type
13.1.7.5. Market Revenue and Forecast, by End User
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy Type
13.2.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.2.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.2.4. Market Revenue and Forecast, by Manufacturing Type
13.2.5. Market Revenue and Forecast, by End User
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy Type
13.2.6.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.2.6.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.2.7. Market Revenue and Forecast, by Manufacturing Type
13.2.8. Market Revenue and Forecast, by End User
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy Type
13.2.9.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.2.9.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.2.10. Market Revenue and Forecast, by Manufacturing Type
13.2.11. Market Revenue and Forecast, by End User
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy Type
13.2.12.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.2.12.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.2.12.4. Market Revenue and Forecast, by Manufacturing Type
13.2.13. Market Revenue and Forecast, by End User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy Type
13.2.14.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.2.14.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.2.14.4. Market Revenue and Forecast, by Manufacturing Type
13.2.15. Market Revenue and Forecast, by End User
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy Type
13.3.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.3.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.3.4. Market Revenue and Forecast, by Manufacturing Type
13.3.5. Market Revenue and Forecast, by End User
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy Type
13.3.6.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.3.6.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.3.6.4. Market Revenue and Forecast, by Manufacturing Type
13.3.7. Market Revenue and Forecast, by End User
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy Type
13.3.8.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.3.8.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.3.8.4. Market Revenue and Forecast, by Manufacturing Type
13.3.9. Market Revenue and Forecast, by End User
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy Type
13.3.10.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.3.10.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.3.10.4. Market Revenue and Forecast, by Manufacturing Type
13.3.10.5. Market Revenue and Forecast, by End User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy Type
13.3.11.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.3.11.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.3.11.4. Market Revenue and Forecast, by Manufacturing Type
13.3.11.5. Market Revenue and Forecast, by End User
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy Type
13.4.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.4.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.4.4. Market Revenue and Forecast, by Manufacturing Type
13.4.5. Market Revenue and Forecast, by End User
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy Type
13.4.6.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.4.6.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.4.6.4. Market Revenue and Forecast, by Manufacturing Type
13.4.7. Market Revenue and Forecast, by End User
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy Type
13.4.8.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.4.8.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.4.8.4. Market Revenue and Forecast, by Manufacturing Type
13.4.9. Market Revenue and Forecast, by End User
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy Type
13.4.10.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.4.10.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.4.10.4. Market Revenue and Forecast, by Manufacturing Type
13.4.10.5. Market Revenue and Forecast, by End User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy Type
13.4.11.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.4.11.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.4.11.4. Market Revenue and Forecast, by Manufacturing Type
13.4.11.5. Market Revenue and Forecast, by End User
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy Type
13.5.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.5.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.5.4. Market Revenue and Forecast, by Manufacturing Type
13.5.5. Market Revenue and Forecast, by End User
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy Type
13.5.6.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.5.6.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.5.6.4. Market Revenue and Forecast, by Manufacturing Type
13.5.7. Market Revenue and Forecast, by End User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy Type
13.5.8.2. Market Revenue and Forecast, by Indication / Therapeutic Area
13.5.8.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)
13.5.8.4. Market Revenue and Forecast, by Manufacturing Type
13.5.8.5. Market Revenue and Forecast, by End User
14.1. Alnylam Pharmaceuticals Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Amgen Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Biogen Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. CORESTEM Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Dendreon Pharmaceuticals LLC.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Helixmith Co. Ltd.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. JCR Pharmaceuticals Co. Ltd.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Kolon TissueGene Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Novartis AG
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Pfizer Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description